<DOC>
	<DOCNO>NCT02216890</DOCNO>
	<brief_summary>This study examine safety profile SGN-CD70A . The study test increase dos SGN-CD70A give every 3 week ( alternate dosing schedule every 6 week ) small group patient . The goal find high dose SGN-CD70A give patient without cause unacceptable side effect . The pharmacokinetics antitumor activity SGN-CD70A also evaluate .</brief_summary>
	<brief_title>Safety Study SGN-CD70A Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Metastatic renal cell carcinoma , mantle cell lymphoma , diffuse large Bcell lymphoma include Grade 3b follicular lymphoma Relapsed , refractory , progressive disease follow least 2 prior systemic therapy Confirmed positive CD70 expression tumor tissue Eastern Cooperative Oncology Group performance status 0 1 Adequate baseline hematologic , pulmonary , renal , hepatic function Measurable disease Prior treatment antiCD70 direct therapy unless CD70 expression confirm tumor tissue obtain treatment Patients &lt; 100 day since prior allogeneic stem cell transplant Less 4 week since prior treatment ; 2 week patient experience disease progression prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Mantle-Cell Lymphoma</keyword>
	<keyword>Diffuse , Large B-Cell , Lymphoma</keyword>
	<keyword>Follicular Lymphoma , Grade 3</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>CD70 Antigen</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>